FIELD: biotechnology.
SUBSTANCE: described are anti-Claudin 18.2 antibody or an antigen-binding fragment thereof, an antibody-drug conjugate for treating or preventing an oncological disease associated with Claudin 18.2 expression, an isolated polynucleotide encoding said antibody or antigen-binding fragment thereof, a nucleic acid construct for treating or preventing an oncological disease expressing Claudin 18.2, a host cell expressing anti-Claudin 18.2 antibody or an antigen-binding fragment thereof, a pharmaceutical composition for treating or preventing an oncological disease associated with Claudin 18.2 expression, a method of producing anti-Claudin 18.2 antibody or an antigen-binding fragment thereof and using the antibody or antigen-binding fragment thereof, an antibody-drug conjugate, a polynucleotide, a nucleic acid construct or a pharmaceutical composition in the manufacture of a drug for treating or preventing oncological disease expressing Claudin 18.2.
EFFECT: invention extends the range of agents binding to Claudin 18.2.
23 cl, 9 dwg, 8 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
TETRAVALENT SYMMETRICAL BISPECIFIC ANTIBODIES | 2019 |
|
RU2807346C2 |
ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
Authors
Dates
2024-02-27—Published
2022-05-07—Filed